共 50 条
- [41] Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b studyLANCET ONCOLOGY, 2014, 15 (09) : 1019 - 1026Younes, AnasThieblemont, CatherineMorschhauser, FranckFlinn, IanFriedberg, Jonathan W.Amorim, SandyHivert, BenedicteWestin, JasonVermeulen, JessicaBandyopadhyay, Nibeditade Vries, RonaldBalasubramanian, SriramHellemans, PeterSmit, Johan W.Fourneau, NeleOki, Yasuhiro
- [42] ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Sehn, Laurie HelenKahl, Brad S.Matasar, Matthew J.Lenz, GeorgIzutsu, KojiZhao, WeiliTao, LinCalvo, RoserZinzani, Pier Luigi
- [43] Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study In Treatment-Naive Patients With CD20-Positive B-Cell Non-Hodgkin's Lymphoma (NHL)BLOOD, 2013, 122 (21)Younes, AnasFlinn, IanBerdeja, JesusFriedberg, Jonathan W.Casulo, CarlaThieblemont, CatherineMorschhauser, FranckWestin, Jason R.Seetharam, ShobhaHellemans, PeterSmit, Hansde Vries, RonaldDauphinee, ElisaBadamo-Dotzis, JulieFourneau, NeleOki, Yasuhiro
- [44] Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm StudyBLOOD, 2022, 140 : 9478 - 9479Davies, Andrew J.Caddy, JoshMcLaughlin, KatyWignall, ChristopherWaugh, RobertCollins, Graham P.Stanton, LouiseSaunders, Geoff N.Cummin, ThomasSchuh, AnnaArdeshna, Kirit M.McMillan, Andrew K.Radford, JohnLewis, David JohnColeman, Adam R.Griffiths, GarethBurton, CathyBarrans, SharonJohnson, Peter
- [45] Pharmacokinetics and Pharmacodynamics in First-MIND: A Phase Ib, Open-Label, Randomized Study of Tafasitamab ± Lenalidomide plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S352 - S352Belada, DavidKopeckova, KaterinaBurgues, Juan Miguel BerguaStevens, DonNowakowski, Grzegorz S.Waldron-Lynch, MaeveHadar, NiraWeirather, JohannesLaessig, CharlotteBlair, DerekDreyling, Martin
- [46] Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma: First Safety, Efficacy, and Biomarker Analyses From the Phase II CAVALLI StudyCLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 15 - 16不详
- [47] Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cyclesLANCET, 2013, 381 (9880) : 1817 - 1826Cunningham, DavidHawkes, Eliza A.Jack, AndrewQian, WendiSmith, PaulMouncey, PaulPocock, ChristopherArdeshna, Kirit M.Radford, John A.McMillan, AndrewDavies, JohnTurner, DeborahKruger, AntonJohnson, PeterGambell, JoannaLinch, David
- [48] A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)BLOOD, 2018, 132Younes, AnasSehn, Laurie H.Johnson, PeterZinzani, Pier LuigiHong, XiaonanZhu, JunSamoilova, OlgaSuh, CheolwonMatsumura, ItaruLopez-Hernandez, AndresDuehrsen, UlrichThieblemont, CatherineCarey, JodiLiu, GraceShreeve, S. MartinSun, StevenVermeulen, JessicaStaudt, Louis M.Wilson, Wyndham H.
- [49] Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI StudyBLOOD, 2018, 132Morschhauser, FranckFeugier, PierreFlinn, Ian W.Gasiorowski, Robin E.Greil, RichardIlles, ArpadJohnson, Nathalie A.Larouche, Jean-FrancoisLugtenburg, Pieternella J.Patti, CaterinaSalles, GillesTrneny, Marekde Vos, SvenMir, FarheenKornacker, MartinPunnoose, Elizabeth A.Samineni, DivyaSzafer-Glusman, EdithPetrich, AdamSinha, ArijitMobasher, MehrdadZelenetz, Andrew D.
- [50] ECHELON-2 (NCT01777152), a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone versus cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with CD30-positive peripheral T-cell lymphoma: 5-year resultsBRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 38 - 40Illidge, TimothyHorwitz, Steven M.O'Connor, Owen A.Pro, BarbaraIyer, Swami P.Advani, RanjanaBartlett, Nancy L.Christensen, Jacob HaaberMorschhauser, FranckDomingo-Domenech, EvaRossi, GiuseppeKim, Won SeogFeldman, Tatyana A.Menne, TobiasBelada, DavidIlles, ArpadTobinai, KenseiTsukasaki, KunihiroYeh, Su-PengHuettmann, AndreasSavage, Kerry J.Yuen, SamZinzani, Pier LuigiMiao, HarryBunn, VeronicaFenton, KeenanFanale, Michelle A.Puhlmann, MarkusTruemper, Lorenz